Sains Malaysiana 41(8)(2012): 961–967

Antifungal Susceptibility Patterns Among Candida Species Isolated from

Blood at Universiti Kebangsaan Malaysia Medical Centre

(Corak Kerentanan Antikulat di Kalangan SpesiesCandida yang dipencil daripada

Darah di Pusat Perubatan Universiti Kebangsaan Malaysia)

Siti Umairah Binti Hamid, Sharon Tan, Siti Nurwani Binti Ahmad Ridzuan, Mohd Syazwan Bin

Che Seman, Ramliza Binti Ramli & Tzar Mohd Nizam Bin Khaithir*

Department of Medical Microbiology and Immunology, Faculty of Medicine

Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak

56000 Cheras Kuala Lumpur, Malaysia

Diserahkan: 13 October 2011 / Diterima: 15 March 2012

ABSTRACT

Many challenges arise in candidaemia treatment which involves emergence of antifungal resistance. New species have been identified due to improved methods of detection and some are resistant to commonly prescribed antifungal agents such as fluconazole and amphotericin B. Therefore, the objective of the study was to observe any changes in the susceptibility patterns and distribution of Candida species. This cross sectional study was conducted at the Department of Medical Microbiology and Immunology in UKMMC, a tertiary teaching hospital. One hundred and fifty one data were collected from the department’s laboratory records from January 2008 to December 2010. The yeasts were identified using ID32C carbohydrate assimilation tests whilst the antifungal susceptibility test was performed using Sensititre® YeastOne® broth microdilution method. Antifungal agents tested included amphotericin B, fluconazole, itraconazole, voriconazole, 5-flucytosine and caspofungin. Out of 151 blood isolates, 47 (31.1%) were Candida albicansand 104 (68.9%) were non-albicansCandida species. Candida tropicalishas surpassed C. albicansas the most commonly isolated Candida species from blood. Overall susceptibility (as compared to 2005-2006 data in brackets) to caspofungin was 99.3% (n/a), 5-flucytosine 97.4% (98%), amphotericin B 94.7% (100%), voriconazole 92.7% (98%), fluconazole 86.8% (90%) and itraconazole 39.1% (40%). In conclusion, although the isolates were generally still susceptible to amphotericin B and fluconazole, resistance to these drugs is increasing.

Keywords: Antifungal resistance; antifungal susceptibility; Candida; candidaemia

ABSTRAK

Banyak cabaran timbul dalam rawatan kandidemia melibatkan kemunculan kerintangan antikulat. Spesies baru telah dikenal pasti selaras dengan penambahbaikan kaedah pengenalpastian dan sebahagiannya adalah rintang terhadap antikulat yang biasa diberi seperti flukonazol dan amfoterisin B. Oleh itu, tujuan kajian ini adalah untuk memerhati sebarang perubahan dalam corak-corak kerentanan dan taburan spesiesCandida. Kajian keratan rentas ini telah dilakukan di Jabatan Mikrobiologi dan Imunologi Perubatan di PPUKM, sebuah hospital pengajar tertier. Data telah dikumpul daripada rekod makmal jabatan dari Januari 2008 hingga Disember 2010. Yis-yis telah dikenal pasti dengan menggunakan ujian asimilasi karbohidrat ID32C manakala ujian kerentanan antikulat telah dilakukan dengan kaedah pencairan kaldu mikro Sensititre® YeastOne®. Agen-agen antikulat yang diuji termasuk amfoterisin B, flukonazol, itrakonazol, vorikonazol, 5-flusitosin dan kaspofungin. Daripada 151 isolat darah, 47 (31.1%) adalah Candida albicansdan 104 (68.9%) adalah spesies bukan-albicans Candida. Candida tropicalis telah mengatasiC. albicans sebagai spesisCandida yang paling kerap dipencil daripada darah. Kerentanan keseluruhan (dibandingkan dengan data 2005-2006 dalam kurungan) terhadap kaspofungin adalah 99.3% (n/a), 5-flukitosin 97.4% (98%), amfotericin B 94.7% (100%), vorikonazol 92.7% (98%), flukonazol 86.8% (90%) dan itrakonazol 39.1% (40%). Kesimpulannya, walaupun isolat-isolat secara umumnya masih rentan terhadap amfoterisin B dan flukonazol, kerintangan terhadap ubatan ini semakin bertambah.

Kata kunci: Candida; Kandidemia; kerentanan antikulat; kerintangan antikulat

RUJUKAN

Cuenca-Estrella, M., Rodero, L., Garcia-Effron, G. & Rodriguez-Tudela, J.L. 2002. Antifungal susceptibility of Candida spp. isolated from blood in Spain and Argentina, 1996-1999. J. Antimicrob. Chemother. 49: 981-987.

Hospenthal, D.R. & Bennett, J.E. 1998. Flucytosine monotherapy for cryptococcosis. Clin. Infect. Dis. 27(2): 260-264.

Kalkanci, A., Berk, E., Aykan, B., Caglar, K., Hizel, K., Arman, D., et al. 2007. Epidemiology and antifungal susceptibility of Candida spp. isolated from hospitalized patients. J. Mycol. Medi. 17: 16-20.

Kothavade, R.J., Kura, M.M., Valand, A.G. & Panthaki, M.H. 2010. Candida tropicalis: Its prevalence, pathogenicity and increasing resistance to fluconazole. J. Med. Microbiol. 59: 873-880.

Luzzaro, F., Ortisi, G., Larosa, M., Drago, M., Brigante, G. & Gesu, G. 2011. Prevalence and epidemiology of microbial pathogens causing bloodstream infections: results of the OASIS multicenter study. Diagn. Microbiol. Infect. Dis. 69: 363-369.

Pfaller, M.A., Diekema, D.J., Jones, R.N., Messer, S.A., Hollis, R.J. & the SENTRY participants group. 2002. Trends in antifungal susceptibility of Candida spp isolated from pediatric and adult patients with bloodstream infections: SENTRY antimicrobial surveillance program, 1997 to 2000. J. Clin. Microbiol. 40(3): 852-856.

Pfaller, M.A., Messer, S.A., Moet, G.J., Jones, R.N. & Castanheira, M. 2011. Candida bloodstream infections: comparison of

species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009), Int. J. Antimicrob. Agents. doi:10.1016/j.ijantimicag.2011.02.016.

Playford, E.G., Marriott, D., Nguyen, Q., Chen, S., Ellis, D. & Slavin, M. 2008. Candidemia in nonneutropenic critically ill patients: Risk factors for non-albicans Candida spp. Crit. Care. Med. 36(7): 2034-2039.

Takakura, S., Fujihara, N., Saito, T., Kudo, T., Iinuma, Y., Ichiyama, S. & the Japan Invasive Mycosis Surveillance Study Group 2003. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconaloze and micafungin. J. Antimicrob. Chemother. 53(2): 283-289.

Tortorano, A.M., Rigoni, A.L., Biraghi, E., Prigitano, A., Viviani, M.A. & the FIMUA-ECMM candidaemia study group. 2003. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibily patterns of 261 non-albicans Candida isolates from blood. J. Antimicrob. Chemother. 52: 679-682.

Trick, W.E., Fridkin, S.K., Edwards, J.R., Hajjeh, R.A., Gaynes, R.P. & the National Nosocomial Infections Surveillance System Hospitals. 2002. Secular Trend of Hospital-Acquired Candidaemia among Intensive Care Unit Patients in the United States during 1989-1999. Clin. Infect. Dis. 35: 627-630.

Tzar, M.N. & Shamim, A.S. 2009. Candidaemia and antifungal susceptibility testing in a teaching hospital. Med. J. Malaysia 64(1): 61-64.

Wenzel, R.P. & Edmond, M.B. 2001. The impact of hospital-acquired bloodstream infections. Emerg. Infect. Dis. 7(2): 174-177.

Xess, I., Jain, N., Hasan, F., Mandal, P. & Banerjee, U. 2007. Epidemiology candidaemia in a tertiary care centre of north India: 5-year study. Infection 35(4): 256-259.

Zepelin, M.B., Kunz, L., Ruchel, R., Reichard, U., Weig, M. & Grob, U. 2007. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. J. Antimicrob. Chemother. 60: 424-428.

*Pengarang surat-menyurat; email: tzarmohdnizam@yahoo.com